Out-of-pockets costs were higher among those using branded or more recently launched drugs.
Patricia Weiser, Pharm.D.
Advertisement
Articles by Patricia Weiser, Pharm.D.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
3
How PBMs are tackling behavioral health
4
The women’s health conversation still has a migraine-sized gap
5